Related Experiment Videos

Rationale for combination therapy as initial treatment for hypertension

Thomas D Giles1

  • 1Louisiana State University School of Medicine, New Orleans, LA 70112, USA. tgiles@lsuhsc.edu

Journal of Clinical Hypertension (Greenwich, Conn.)
|August 28, 2003
PubMed

Insights

For patients with high blood pressure, starting with two or more medications (combination therapy) is more effective than one drug. This approach helps patients reach their blood pressure goals faster and may reduce side effects.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Current hypertension guidelines suggest initiating antihypertensive therapy with multiple agents for patients significantly above their blood pressure goals.
  • Monotherapy may be insufficient for patients with elevated blood pressure, necessitating combination therapy.
  • Combination therapy can offer improved adherence and potentially fewer adverse effects compared to high-dose monotherapy.

Purpose of the Study:

  • To discuss the rationale behind using combination antihypertensive therapy as initial treatment for selected patients with high blood pressure.
  • To review study data evaluating the efficacy of a fixed-dose combination product versus high-dose monotherapy in managing Stage 2 hypertension.

Main Methods:

  • A study involving 364 high-risk patients with Stage 2 hypertension was conducted.
  • Patients received either a fixed-dose combination product (amlodipine besylate/benazepril HCl) or high-dose monotherapy (amlodipine besylate) as initial treatment.
  • Blood pressure reduction was the primary outcome measure.

Main Results:

  • The fixed-dose combination product (amlodipine besylate/benazepril HCl) demonstrated greater success in reducing blood pressure compared to high-dose monotherapy (amlodipine besylate).
  • Initial combination therapy proved more effective in achieving blood pressure goals in this patient cohort.

Conclusions:

  • Initial combination antihypertensive therapy is a rational and effective strategy for selected patients with Stage 2 hypertension.
  • Fixed-dose combination products can be a valuable tool for achieving rapid and effective blood pressure control.
  • Prompt achievement of blood pressure goals is crucial for improving clinical outcomes in hypertensive patients.

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...